Citations

Showing 10 of 107961 citations.

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
Dimopoulos, Meletios Α. , Kyle, Robert A. , Fermand, Jean-Paul, Rajkumar, S. Vincent , Miguel, Jesús F. San , Chanan‐Khan, Asher , Joshua, Douglas, Mehta, Jayesh, Avet‐Loiseau, Hervé , Beksaç, Meral , Moreau, Philippe , Goldschmidt, Hartmut , Boccadoro, Mario , Kumar, Shaji , Munshi, Nikhil C. , 3, on behalf of the International Myeloma Workshop Consensus Panel, Ludwig, Heinz , Gertz, Morie A. , Anderson, Kenneth C. , Singhal, Seema , Giralt, Sergio , Jagannath, Sundar , 3, on behalf of the International Myeloma Workshop Consensus Panel, Rajkumar, S Vincent , Dimopoulos, Meletios A , Moreau, Philippe , San-Miguel, Jesus , Beksac, Meral

Mayo Clinic

Blood | February 4, 2011 | Volume: 117 | Issue: 18 | Pages: 4701-4705

10.1182/blood-2010-10-299529 | PMID 21292778 Get It

AbstractA panel of members of the 2009 International Myeloma Workshop developed guidelines for standard investigative workup of patients with suspected multiple myeloma. Both serum and urine should be assessed for monoclonal protein. Measurement of monoclonal protein both by densitometer tracing and/by nephelometric quantitation is recommended, and immunofixation is required for confirmation. The serum-free light chain assay is recommended in all newly diagnosed patients with plasma cell dyscrasias. Bone marrow aspiration and/or biopsy along with demonstration of clonality of plasma cells are necessary. Serum β2-microglobulin, albumin, and lactate dehydrogenase are necessary for prognostic purposes. Standard metaphase cytogenetics and fluorescent in situ hybridization for 17p, t(4;14), and t(14;16) are recommended. The skeletal survey remains the standard method for imaging screening, but magnetic resonance imaging frequently provides valuable diagnostic and prognostic information. Most of these tests are repeated during follow-up or at relapse.
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
Rajkumar, S. Vincent , Harousseau, Jean‐Luc, Durie, Brian G.M. , Dimopoulos, Meletios Α. , Kyle, Robert A. , Bladé, Joan , Richardson, Paul G. , Orlowski, Robert Z. , Avet‐Loiseau, Hervé , Palumbo, Antonio , Zonder, Jeffrey A. , Vesole, David H., Sezer, Orhan , Munshi, Nikhil C. , Miguel, Jesús F. San , 1, on behalf of the International Myeloma Workshop Consensus Panel, Cavo, Michèle , García‐Sánz, Ramón , Anderson, Kenneth C. , Richardson, Paul Gerard Guy , Orlowski, Robert Z. , Siegel, David S. , Jagannath, Sundar , Facon, Thierry T.F. , Lonial, Sagar , Ludwig, Heinz , 1, on behalf of the International Myeloma Workshop Consensus Panel, Rajkumar, S Vincent , Dimopoulos, Meletios A , San-Miguel, Jesus , Garcia-Sanz, Ramon

Mayo Clinic

Blood | February 4, 2011 | Volume: 117 | Issue: 18 | Pages: 4691-4695

10.1182/blood-2010-10-299487 | PMID 21292775 Get It

Abstract It is essential that there be consistency in the conduct, analysis, and reporting of clinical trial results in myeloma. The goal of the International Myeloma Workshop Consensus Panel 1 was to develop a set of guidelines for the uniform reporting of clinical trial results in myeloma. This paper provides a summary of the current response criteria in myeloma, detailed definitions for patient populations, lines of therapy, and specific endpoints. We propose that future clinical trials in myeloma follow the guidelines for reporting results proposed in this manuscript.
Contribution of adenosine to compensatory dilation in hypoperfused contracting human muscles is independent of nitric oxide
Casey, Darren P. , Joyner, Michael J.

Mayo Clinic

Journal of Applied Physiology | February 3, 2011 | Volume: 110 | Issue: 5 | Pages: 1181-1189

10.1152/japplphysiol.00836.2010 | PMID 21292838 Get It

We previously demonstrated that nitric oxide (NO) contributes to compensatory vasodilation in the contracting human forearm subjected to acute hypoperfusion. We examined the potential role of an adenosine-NO interaction to this response in 17 male subjects (25 ± 2 yr). In separate protocols subjects performed rhythmic forearm exercise (20% of maximum) while hypoperfusion was evoked by balloon inflation in the brachial artery above the elbow. Each trial included exercise before inflation, exercise with inflation, and exercise after deflation (3 min each). Forearm blood flow (FBF; ultrasound) and local [brachial artery catheter pressure (BAP)] and systemic [mean arterial pressure (MAP); Finometer] arterial pressure were measured. In protocol 1 ( n = 10), exercise was repeated during nitric oxide synthase inhibition [ NG-monomethyl-l-arginine (l-NMMA)] alone and during l-NMMA-aminophylline (adenosine receptor blockade) administration. In protocol 2, exercise was repeated during aminophylline alone and during aminophylline-l-NMMA. Forearm vascular conductance (FVC; ml·min−1·100 mmHg−1) was calculated from blood flow (ml/min) and BAP (mmHg). Percent recovery in FVC during inflation was calculated as (steady-state inflation + exercise value − nadir)/[steady-state exercise (control) value − nadir]. In protocol 1, percent recovery in FVC was 108 ± 8% during the control (no drug) trial. Percent recovery in FVC was attenuated with inhibition of NO formation alone (78 ± 9%; P < 0.01 vs. control) and was attenuated further with combined inhibition of NO and adenosine (58 ± 9%; P < 0.01 vs. l-NMMA). In protocol 2, percent recovery was reduced with adenosine receptor blockade (74 ± 11% vs. 113 ± 6%, P < 0.01) compared with control drug trials. Percent recovery in FVC was attenuated further with combined inhibition of adenosine and NO (48 ± 11%; P < 0.05 vs. aminophylline). Our data indicate that adenosine contributes to compensatory vasodilation in an NO-independent manner during exercise with acute hypoperfusion.
Impact of a Housing First Program on Health Utilization Outcomes Among Chronically Homeless Persons
DeSilva, Malini B. , Manworren, Julie, Targonski, Paul V.

Mayo Clinic

Journal of Primary Care & Community Health | February 3, 2011 | Volume: 2 | Issue: 1 | Pages: 16-20

10.1177/2150131910385248 | PMID 23804657 Get It

The authors examined the impact of a Housing First program on the use of specific health services, detoxification services, and criminal activity of long-term homeless individuals. The study sample consisted of eligible members of the inception cohort (18 enrollees) in the Single Adults Residential Assistance program (SARA) in Minneapolis, Minnesota. Analyses examined participant housing stability after enrollment in SARA and compared the use of a county medical center, detoxification programs, and criminal activity in the 2 years before and after enrollment in SARA. Only 1 of the 18 enrollees studied experienced homelessness during the 2-year follow-up after enrollment in SARA. There was a significant reduction in the amount of criminal activity in the 2-year period after SARA enrollment. The direction of association observed for other service uses remained consistent with expectations in existing literature, but were not statistically significant. Supportive housing for chronically homeless individuals may be successful at decreasing homelessness among this fragile population and may help reduce criminal activity.
Setting the Bar for Laparoscopic Resection of Sporadic Insulinoma
Richards, Melanie L. , Thompson, Geoffrey B. , Farley, David R. , Kendrick, Michael L. , Service, John F., Grant, Clive S., Vella, Adrian

Mayo Clinic

World Journal of Surgery | February 3, 2011 | Volume: 35 | Issue: 4 | Pages: 785-789

10.1007/s00268-011-0970-5 | PMID 21293961 Get It

AbstractBackgroundLaparoscopic insulinoma resection (LIR) for sporadic disease is increasingly supported as a feasible and safe operation in small series of patients. To determine whether LIR is an acceptable alternative to the open operation, it is necessary to compare LIR to historical controls. The purpose of this study was to identify the skills and technology needed for LIR and establish outcome standards.MethodsA database of patients with benign sporadic insulinoma who underwent an open procedure at the Mayo Clinic was reviewed for demographics, imaging, operative/pathology reports, and outcomes. Outcomes were compared to a world‐wide meta‐analysis of patients who had undergone LIR reported in the English literature between 1996 and 2009.ResultsTwo hundred fifteen patients underwent a primary open operation for benign sporadic insulinoma. Solitary tumors were found in 97%. Meta‐analysis identified 232 patients who underwent LIR. The open and LIR groups underwent comparable operations that included enucleations (64 vs. 68%) and distal pancreatectomies (28 vs. 35%) (p = 0.06). The mean estimated blood loss, operating time, and length of stay were comparable between the open and LIR groups (p = NS). Pancreatic fistula occurred more often in the LIR group (24 vs. 11%, p < 0.05). A curative operation was performed in 98% of control patients and in 99% of the LIR group (p = NS).ConclusionsMultiple insulinomas are rare and a focused resection guided by imaging may be performed. LIR is associated with an increased incidence of pancreatic fistula. Success of LIR will depend on accurate multimodality preoperative imaging, skilled use of lap‐US to replace palpation for localization, and safe methods to dissect the tumor adjacent to the pancreatic duct.
When the negative is positive
Slager, Susan L.

Mayo Clinic

Blood | February 3, 2011 | Volume: 117 | Issue: 5 | Pages: 1441-1442

10.1182/blood-2010-11-320127 | PMID 21292784 Get It

TRPV4 mutations and cytotoxic hypercalcemia in axonal Charcot-Marie-Tooth neuropathies
Klein, Christopher J. , Shi, Yong , Fecto, Faisal , Donaghy, Michael, Nicholson, Garth A. , McEntagart, Meriel , Crosby, Andrew H. , Lou, H. , McEvoy, Kathleen M., Siddique, Teepu , Deng, Han‐Xiang , Dyck, P. James B. , Wu, Yanhong , Klein, Christopher J

Mayo Clinic

Neurology | February 3, 2011 | Volume: 76 | Issue: 10 | Pages: 887-894

10.1212/wnl.0b013e31820f2de3 | PMID 21288981 Get It

Do old HLA and mitochondrial DNA variants associate with demyelination types in young patients?
Kálmán, Bernadette , Weinshenker, Brian G. , Weinshenker, Brian G

Mayo Clinic

Neurology | February 3, 2011 | Volume: 76 | Issue: 9 | Pages: 768-769

10.1212/wnl.0b013e31820e7bfc | PMID 21288985 Get It

Motor vehicle crashes, suicides, and assaults
Drazkowski, Joseph F., Sirven, Joseph I

Mayo Clinic

Neurology | February 3, 2011 | Volume: 76 | Issue: 9 | Pages: 770-771

10.1212/wnl.0b013e31820e7be6 | PMID 21288989 Get It

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5
Zhu, Yuan Xiao , Tiedemann, Rodger E. , Shi, Chang-Xin, Yin, Holly, Schmidt, Jessica, Bruins, Laura A., Keats, Jonathan J. , Braggio, Esteban , Sereduk, Chris , Mousses, Spyro, Stewart, A. Keith, Braggio, Esteban , Keats, Jonathan J

Mayo Clinic

Blood | February 3, 2011 | Volume: 117 | Issue: 14 | Pages: 3847-3857

10.1182/blood-2010-08-304022 | PMID 21289309 Get It

Abstract The molecular target(s) cooperating with proteasome inhibition in multiple myeloma (MM) remain unknown. We therefore measured proliferation in MM cells transfected with 13 984 small interfering RNAs in the absence or presence of increasing concentrations of bortezomib. We identified 37 genes, which when silenced, are not directly cytotoxic but do synergistically potentiate the growth inhibitory effects of bortezomib. To focus on bortezomib sensitizers, genes that also sensitized MM to melphalan were excluded. When suppressed, the strongest bortezomib sensitizers were the proteasome subunits PSMA5, PSMB2, PSMB3, and PSMB7 providing internal validation, but others included BAZ1B, CDK5, CDC42SE2, MDM4, NME7, RAB8B, TFE3, TNFAIP3, TNK1, TOP1, VAMP2, and YY1. The strongest hit CDK5 also featured prominently in pathway analysis of primary screen data. Cyclin-dependent kinase 5 (CDK5) is expressed at high levels in MM and neural tissues with relatively low expression in other organs. Viral shRNA knockdown of CDK5 consistently sensitized 5 genetically variable MM cell lines to proteasome inhibitors (bortezomib and carfilzomib). Small-molecule CDK5 inhibitors were demonstrated to synergize with bortezomib to induce cytotoxicity of primary myeloma cells and myeloma cell lines. CDK5 regulation of proteasome subunit PSMB5 was identified as a probable route to sensitization.